A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

被引:179
作者
Jänne, PA
Borras, AM
Kuang, YN
Rogers, AM
Joshi, VA
Liyanage, H
Lindeman, N
Lee, JC
Halmos, B
Maher, EA
Distel, RJ
Meyerson, M
Johnson, BE
机构
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Translat Res Lab, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Dept Med Oncol & Canc Biol, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA
[7] Harvard Univ, Sch Med, Dept Biol Chem, Cambridge, MA 02138 USA
[8] Harvard Univ, Sch Med, Dept Mol Pharmacol, Cambridge, MA 02138 USA
[9] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[10] Harvard Partners Ctr Genet & Genom, Mol Med Lab, Cambridge, MA USA
[11] Transgenom Inc, Cambridge, MA USA
[12] Univ Hosp Cleveland, Ireland Canc Ctr, Case Sch Med, Cleveland, OH 44106 USA
关键词
D O I
10.1158/1078-0432.CCR-05-2047
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Mutations in the epidermal growth factor receptor (EGFR) are associated with clinical and radiographic responses to EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Currently available methods of EGFR mutation detection rely on direct DNA sequencing, which requires isolation of DNA from a relatively pure population of tumor cells, cannot be done on small diagnostic specimens, and lack sensitivity. Here we describe the use of a sensitive screening method that overcomes many of these limitations. Experimental Design: We screened 178 non-small cell lung cancer specimens for mutations in exons 18 to 21 of EGFR using a DNA endonuclease, SURVEYOR, which cleaves mismatched heteroduplexed DNA. Samples were analyzed by high-performance liquid chromatography on the Transgenomic WAVE HS system. Selected specimens that produced digestion products using SURVEYOR were subsequently reanalyzed by size separation or under partially denaturing conditions, followed by fractionation and sequencing. The specimens included DNA isolated from frozen tumor specimens, dissected formalin-fixed, paraffin-embedded tumor specimens undergoing clinical sequencing, and undissected formalin-fixed, paraffin-embedded specimens. One hundred sixty specimens were independently analyzed using direct DNA sequencing in a blinded fashion. Results: EGFR mutations were detected in 16 of 61 fresh frozen tumor specimens, 24 of 91 dissected formalin-fixed, paraffin-embedded tumor specimens, and 11 of 26 undissected formalin-fixed, paraffin-embedded tumor specimens. Compared with sequencing, the sensitivity and specificity of the present method were 100% and 87%. The positive and negative predictive values were 74% and 100%, respectively. SURVEYOR analysis detected 7 (4%) mutations that were not previously detected by direct sequencing. Conclusions: SURVEYOR analysis provides a rapid method for EGFR mutation screening with 100% sensitivity and negative predictive value. This unbiased scanning technique is superior to direct sequencing when used with undissected formalin-fixed, paraffin-embedded specimens.
引用
收藏
页码:751 / 758
页数:8
相关论文
共 35 条
[1]  
Bernstein JL, 2002, CANCER EPIDEM BIOMAR, V11, P809
[2]   Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].
Cappuzzo, F ;
Hirsch, FR ;
Rossi, E ;
Bartolini, S ;
Ceresoli, GL ;
Bemis, L ;
Haney, J ;
Witta, S ;
Danenberg, K ;
Domenichini, I ;
Ludovini, V ;
Magrini, E ;
Gregorc, V ;
Doglioni, C ;
Sidoni, A ;
Tonato, M ;
Franklin, WA ;
Crino, L ;
Bunn, PA ;
Varella-Garcia, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655
[3]   Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer [J].
Chou, TY ;
Chiu, CH ;
Li, LH ;
Hsiao, CY ;
Tzen, CY ;
Chang, KT ;
Chen, YM ;
Perng, RP ;
Tsai, SF ;
Tsai, CM .
CLINICAL CANCER RESEARCH, 2005, 11 (10) :3750-3757
[4]   Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients [J].
Cortes-Funes, H ;
Gomez, C ;
Rosell, R ;
Valero, P ;
Garcia-Giron, C ;
Velasco, A ;
Izquierdo, A ;
Diz, P ;
Camps, C ;
Castellanos, D ;
Alberola, V ;
Cardenal, F ;
Gonzalez-Larriba, JL ;
Vieitez, JM ;
Maeztu, I ;
Sanchez, JJ ;
Queralt, C ;
Mayo, C ;
Mendez, P ;
Moran, T ;
Taron, M .
ANNALS OF ONCOLOGY, 2005, 16 (07) :1081-1086
[5]   ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines [J].
Engelman, JA ;
Jänne, PA ;
Mermel, C ;
Pearlberg, J ;
Mukohara, T ;
Fleet, C ;
Cichowski, K ;
Johnson, BE ;
Cantley, LC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) :3788-3793
[6]   Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib [J].
Han, SW ;
Kim, TY ;
Hwang, PG ;
Jeong, S ;
Kim, J ;
Choi, IS ;
Oh, DY ;
Kim, LH ;
Kim, DW ;
Chung, DH ;
Im, SA ;
Kim, YT ;
Lee, JS ;
Heo, DS ;
Bang, YJ ;
Kim, NK .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2493-2501
[7]   Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].
Hanna, N ;
Shepherd, FA ;
Fossella, FV ;
Pereira, JR ;
De Marinis, F ;
von Pawel, J ;
Gatzemeier, U ;
Tsao, TCY ;
Pless, M ;
Muller, T ;
Lim, HL ;
Desch, C ;
Szondy, K ;
Gervais, R ;
Shaharyar ;
Manegold, C ;
Paul, S ;
Paoletti, P ;
Einhorn, L ;
Bunn, PA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597
[8]   High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan [J].
Huang, SF ;
Liu, HP ;
Li, LH ;
Ku, YC ;
Fu, YN ;
Tsai, HY ;
Chen, YT ;
Lin, YF ;
Chang, WC ;
Kuo, HP ;
Wu, YC ;
Chen, YR ;
Tsai, SF .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8195-8203
[9]   EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].
Kobayashi, S ;
Boggon, TJ ;
Dayaram, T ;
Janne, PA ;
Kocher, O ;
Meyerson, M ;
Johnson, BE ;
Eck, MJ ;
Tenen, DG ;
Halmos, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792
[10]   Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck [J].
Lee, JW ;
Soung, YH ;
Kim, SY ;
Nam, HK ;
Park, WS ;
Nam, SW ;
Kim, MS ;
Sun, DI ;
Lee, YS ;
Jang, JJ ;
Lee, JY ;
Lee, SH ;
Yoo, NJ ;
Lee, SH .
CLINICAL CANCER RESEARCH, 2005, 11 (08) :2879-2882